Strong data center demand can prop shares of Forgent Power Solutions higher, Goldman Sachs said. The bank initiated the power infrastructure company, which designs electrical distribution equipment used in data centers and energy-intensive industrial facilities, at a buy rating. Its 12-month price target of $48 implies upside of 40% from here. Forgent Power Solutions went public last month on the ...
Strong data center demand can prop shares of Forgent Power Solutions higher, Goldman Sachs said. The bank initiated the power infrastructure company, which designs electrical distribution equipment used in data centers and energy-intensive industrial facilities, at a buy rating. Its 12-month price target of $48 implies upside of 40% from here. Forgent Power Solutions went public last month on the New York Stock Exchange. Since its first trading day on Feb. 5, the stock has added 27%. FPS 1M mountain FPS 1M chart Analyst Joe Ritchie believes that Forgent is well-positioned in the attractive electrical distribution equipment industry. The industry's total addressable market currently sits at around $35 billion, and he forecasts this to grow around 17.5% through the end of the decade. "Forgent is one of a few companies that can deliver (most products manufactured internally) the entire electrical powertrain for a data center, a capability that is critical for customers who prioritize speed, reliability, and single-source accountability," he wrote. "U.S. electricity demand is projected to increase significantly, driven by data centers and industrial electrification, which necessitates substantial investment in both new power generation and the transmission and distribution (T & D) network." Ritchie added that the reshoring of U.S. manufacturing provides another robust and long-term demand driver for Forgent. The company is also nearing completion on a $205 million investment program to dramatically expand its own manufacturing footprint, designed to support up to $5 billion in annual sales and providing ample opportunity for Forgent to take share. Ritchie also argued that Forgent's custom, engineer-to-order business model positions the company for significant margin expansion as volumes scale. He sees all of these factors propping up Forgent's valuation picture in the next few years. "Relative to peers, we believe FPS' sales and EBITDA growth will significantly outpace ...
(RTTNews) - Early signs from the U.S. Futures suggest that, Wall Street might be bracing for a sharp fall on Monday, in response to escalating geopolitical developments in the West Asia. It is expected that the global supply of crude oil will be severely disrupted and the price w
(RTTNews) - Early signs from the U.S. Futures suggest that, Wall Street might be bracing for a sharp fall on Monday, in response to escalating geopolitical developments in the West Asia. It is expected that the global supply of crude oil will be severely disrupted and the price w
ADMA Biologics ( ADMA ) announced on Monday a capital return initiative target of approximately $200 million during 2026, including the execution of a $125 million accelerated share repurchase (“ASR”) agreement with JPMorgan Chase Bank, National Association. Under the terms of the ASR agreement, ADMA will pay JPMorgan an aggregate upfront amount of $125 million and will initially receive approxima...
ADMA Biologics ( ADMA ) announced on Monday a capital return initiative target of approximately $200 million during 2026, including the execution of a $125 million accelerated share repurchase (“ASR”) agreement with JPMorgan Chase Bank, National Association. Under the terms of the ASR agreement, ADMA will pay JPMorgan an aggregate upfront amount of $125 million and will initially receive approximately 6.4 million shares of its common stock on or about March 3, 2026. This will represent approximately 80% of the shares expected to be repurchased under the ASR, based on the closing price of ADMA’s common stock of $15.57 per share on February 27, 2026. The ASR agreement was executed pursuant to the company’s existing share repurchase program, under which the company has up to $500 million authorized for repurchases. Since the program’s authorization in May 2025, between prior repurchases and the ASR, ADMA will have repurchased approximately $160 million of its common stock to date. The company said that the management believes these actions enhance long-term stockholder value and reflect a disciplined and opportunistic approach to capital allocation. ADMA +0.83% premarket to $15.7. Source: Press Release More on ADMA Biologics ADMA Biologics, Inc. (ADMA) Q4 2025 Earnings Call Transcript ADMA Biologics: Business Update And My Price Target ADMA Biologics, Inc. (ADMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript ADMA forecasts $635M revenue for 2026 as ASCENIV drives margin expansion and new supply deals extend growth runway ADMA Biologics GAAP EPS of $0.20 beats by $0.02, revenue of $139.16M misses by $0.64M
(RTTNews) - Neogen Corporation (NEOG), a food safety solutions provider, Monday announced that it has agreed to sell its genomics business to Zoetis Inc., an animal health company, for $160 million.
(RTTNews) - Neogen Corporation (NEOG), a food safety solutions provider, Monday announced that it has agreed to sell its genomics business to Zoetis Inc., an animal health company, for $160 million.
imaginima/iStock via Getty Images EchoStar ( SATS ) reported a top-line beat for the fourth quarter and the satcom, telecom, and television entertainment services provider saw subscriber losses across all its operating segments. In Q4, revenue fell 4.3% to $3.8B, topping the consensus estimate of $3.79B polled by FactSet. In its Pay-TV unit, subscribers fell by about 168,000, better than the 253,0...
imaginima/iStock via Getty Images EchoStar ( SATS ) reported a top-line beat for the fourth quarter and the satcom, telecom, and television entertainment services provider saw subscriber losses across all its operating segments. In Q4, revenue fell 4.3% to $3.8B, topping the consensus estimate of $3.79B polled by FactSet. In its Pay-TV unit, subscribers fell by about 168,000, better than the 253,000 losses in the year-ago quarter. The company closed Q4 with 7M Pay-TV subscribers, including 5.02M DISH TV subscribers and 1.98M Sling TV subscribers. In Q4 2024, it had 7.78M Pay-TV subscribers, which included 5.69M DISH TV subscribers and 2.09M Sling TV subscribers. Retail wireless subs fell by about 9,000, compared to an increase of 90,000 a year ago, leaving the company with 7.51M users in the segment at quarter end. Broadband subscribers fell by about 44,000, better than the losses of 59,000 last year, closing the quarter with 739,000 users vs. 884,000 reported in Q4 2024. Net loss was $14.5B for 2025, compared to a loss of $124.5M last year, primarily attributable to non-cash asset impairments and other expenses of about $17.63B. Excluding the tax-affected impact of the noncash adjustments for 2025 and 2024, the net loss attributable to EchoStar would have been about $1.05B and $664M, respectively. OIBDA for the quarter was up 47% at $583.7M. SATS shares are down 2.5% in premarket trading on Monday. More on EchoStar EchoStar Remains A Complex Public Proxy For SpaceX EchoStar: Fair For Its Operations, SpaceX For Free EchoStar reports Q4 results EchoStar Q4 2025 Earnings Preview Seeking Alpha’s Quant Rating on EchoStar
Apogee Therapeutics press release ( APGE ): FY net loss of $255.8M. More on Apogee Therapeutics Apogee Therapeutics: 2026 Inflection Point In Immunology Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript Apogee Therapeutics, Inc. (APGE) Presents at Citi Annual Global Healthcare Conference 2025 Transcr...
Apogee Therapeutics press release ( APGE ): FY net loss of $255.8M. More on Apogee Therapeutics Apogee Therapeutics: 2026 Inflection Point In Immunology Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript Apogee Therapeutics, Inc. (APGE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript Seeking Alpha’s Quant Rating on Apogee Therapeutics Historical earnings data for Apogee Therapeutics
S&P 500 Index futures are down 1.2% as of 7:45 a.m. in New York as the eruption of military conflict in Iran rattled global markets. Nasdaq 100 futures fall 1.5% Dow Jones Industrial Average futures drop 1.2% The MSCI World Index is down 0.6% Here are some of the biggest US movers before the bell: Magnificent Seven stocks fall: Microsoft (MSFT) -0.8%, Apple (AAPL) -1%, Nvidia (NVDA) -1.3%, Meta Pl...
S&P 500 Index futures are down 1.2% as of 7:45 a.m. in New York as the eruption of military conflict in Iran rattled global markets. Nasdaq 100 futures fall 1.5% Dow Jones Industrial Average futures drop 1.2% The MSCI World Index is down 0.6% Here are some of the biggest US movers before the bell: Magnificent Seven stocks fall: Microsoft (MSFT) -0.8%, Apple (AAPL) -1%, Nvidia (NVDA) -1.3%, Meta Platforms (META) -1.7%, Amazon (AMZN) -2.4%, Alphabet (GOOGL) -2.6%, Tesla (TSLA) -2.1% The Iran conflict is pushing shares of airlines and cruise operators lower, while energy stocks jump. Movers include American Airlines (AAL) -6% and Exxon (XOM) +4%. US banks and financials are pointing lower as risk off sentiment extends with military strikes intensifying across the Middle East. JPMorgan Chase (JPM) -2%, Wells Fargo (WFC) -1.7%. AES Corp. (AES) falls 16% after a consortium led by Global Infrastructure Partners and EQT agreed to buy the electric utility. Berkshire Hathaway (BRK/B) slips 1% after the conglomerate’s operating profits fell nearly 30% in Warren Buffett’s last quarter as CEO. Analysts note weakness in the company’s insurance businesses. EchoStar (SATS) declines 2% after the parent of Dish Network posted a net loss in the fourth quarter. Paramount Skydance (PSKY) rises 5% after Warner Bros. Discovery filed a join-statement following the market close on Friday announcing that they had entered into a definitive merger agreement. UniQure (QURE) tumbles 41% after US regulators said the company should conduct a pivotal study before getting approval of its gene therapy for Huntington’s disease, another example of the Trump administration slowing a treatment for a rare disease drug.
EchoStar (SATS) delivered earnings and revenue surprises of -21.89% and +1.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
EchoStar (SATS) delivered earnings and revenue surprises of -21.89% and +1.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Three US F-15s Downed Over Kuwait As Iran War Spirals, Reports Of 'Paranoia, Anxiety' At Pentagon It is only day three of 'Operation Epic Fury' and Americans are waking up to shocking images of US fighter jets going down over Kuwait , and the incredibly rare scene of pilots parachuting down with a look of disbelief and confusion... Kuwait's defense ministry says "several" US military aircraft have...
Three US F-15s Downed Over Kuwait As Iran War Spirals, Reports Of 'Paranoia, Anxiety' At Pentagon It is only day three of 'Operation Epic Fury' and Americans are waking up to shocking images of US fighter jets going down over Kuwait , and the incredibly rare scene of pilots parachuting down with a look of disbelief and confusion... Kuwait's defense ministry says "several" US military aircraft have crashed https://t.co/Tvaq4zFrEY pic.twitter.com/SLaSYWwZep — CNN (@CNN) March 2, 2026 US CENTCOM has confirmed, following a Kuwaiti government statement, "At 11:03 p.m. ET, March 1, three U.S. F-15E Strike Eagles flying in support of Operation Epic Fury went down over Kuwait due to an apparent friendly fire incident." That's three US warplanes in apparently one incident. How does that happen? Of course, given the already thick fog of war and propaganda narratives fast going back and forth, it's entirely possible they could have been shot down by Iranian defenses or jets from just across the border. Iran is saying it has shot down at least one US F-15 fighter jet : IRAN SAYS IT SHOT DOWN US F-15 FIGHTER JET: TASNIM Here's the fuller CENTCOM narrative: CENTCOM: “During active combat—that included attacks from Iranian aircraft, ballistic missiles, and drones — the U.S. Air Force fighter jets were mistakenly shot down by Kuwaiti air defenses . All six aircrew ejected safely, have been safely recovered, and are in stable condition. Kuwait has acknowledged this incident, and we are grateful for the efforts of the Kuwaiti defense forces and their support in this ongoing operation.” American pilot found by Kuwait police and locals, via X. Given there's now an official Pentagon casualty/death count, and given the fact that the Gulf allies and especially Israel are getting hit hard by Iran's significant ballistic missile arsenal, President Trump himself may now be (only too late) realize he just bit off more than he can chew in ordering this ultra-risky regime change operation . The...